caski  (ATCC)

Journal: Neoplasia (New York, N.Y.)

Article Title: PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy

doi: 10.1016/j.neo.2026.101305

Figure Lengend Snippet: Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) CaSki cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) SiHa ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.

Article Snippet: CC cell lines, including CaSki (ATCC Cat# CRM-CRL-1550_Ca Ski, RRID: CVCL_1100), SiHa (ATCC Cat# HTB-35_SiHa, RRID: CVCL_0032), and ME180 (ATCC Cat# HTB-33_ME-180, RRID: CVCL_1401), C33A (ATCC CRM-HTB-31, RRID:CVCL_1094) were obtained from ATCC.

Techniques: Expressing

Journal: Nature Genetics

Article Title: High-content CRISPR activation screens identify synthetically lethal RNA-based mechanisms to sensitize cancer cells to targeted T cell cytotoxicity

doi: 10.1038/s41588-026-02561-7

Figure Lengend Snippet: a , MYC ORF-based overexpression sensitizes cervical cancer cells to T cell cytotoxicity. The fraction of surviving HPV + cervical cancer cells ( y axis) in coculture with E7 TCR T cells (1:1, 48 h), is shown for CaSki cells transduced to express a control, BID or MYC ORF (mean ± s.d., n = 3 technical replicates per ORF). **** P < 0.001, ordinary one-way ANOVA, Dunnett’s multiple-comparison test. b , Fold-change in A375 cell viability after 24-h treatment with FasL (200 ng ml −1 ), shown for A375 cells with ORF-based overexpression of different sensitizing hits compared to A375 cells with a control ORF (mean ± s.d., n = 3–6 technical replicates per ORF). **** P < 0.0001, ** P < 0.01, ordinary one-way ANOVA, Dunnett’s multiple-comparison test, compared to control cells. c , UMAP of Perturb-seq data of control (NTC) and MYC CRISPRa cells, colored based on: (1) culture conditions, (2) sgRNA and MYC expression level, (3) the expression of the MYC GA signature and (4) the expression of the CRISPRa-resistance hit GAS7 (log 2 1p-transformed tp100k). d , Expression of MYC GA signature in control (NTC) cells and cells with MYC CRISPRa sgRNAs, further stratified based on MYC expression in monoculture (left) and coculture (right). The number of cells in each group is shown in parentheses ( n ). Boxplots: the middle line shows the median, the box edges show the 25th and 75th percentiles and the whiskers show the most extreme points that do not exceed ±1.5× the interquartile range (IQR). Further outliers are marked individually with circles (minima or maxima). **** P < 0.0001, one-tailed Student’s t -test.

Article Snippet: The cervical cancer cell line CaSki (ATCC, cat. no. CRL-1550) was cultured in Roswell Park Memorial Institute (RPMI) medium with GlutaMAX (Gibco, cat. no. 72400-047) supplemented with 10% FBS and 1× Pen–Strep.

Techniques: Over Expression, Control, Comparison, Expressing, Transformation Assay, One-tailed Test